Pioneer in evidence-based medicine ends year with 25 percent growth in
revenues, expanded leadership team, increased customer base and new product
lines
DEDHAM, Mass., Feb. 14 /PRNewswire/ -- Signet Laboratories, a pioneer in
evidence-based medicine (EviMed), today announced that its 2004 fiscal year
revenue reflects a 25% increase over 2003.
Signet's revenue increase over the past year is attributable to growth in
both the U.S. and international markets, as well as sales growth in the
company's Neuroscience and Immunohistochemistry product lines.
In addition, the company launched a series of key new products this year,
including a number of RUO diagnostics such as the ABP-26(TM) and
NEPHROSCREEN(TM) assays for detection of Sepsis and Acute Renal Failure
(SARF), respectively; the Apo-J(TM) antibody and Beta Amyloid 1-40/1-42(TM)
ELISA kits for detecting Alzheimer's Disease; DJ-1(TM) for Parkinson's
Disease; P504s(TM) IVD for prostate cancer; and the ACUITY(TM) Mouse-on-Mouse
Polymer Detection System.
Signet has also expanded its leadership team this year with key executive
hires, including a new Chief Financial Officer, a new Vice President of
Production & Development, and a Director of Production & Manufacturing.
"We're tremendously pleased by the results we've seen this year," said Dr.
Richard D. Gill, President and CEO of Signet Laboratories. "It's a testament
to the strength of our business, built over many successful years, as well as
our plans to take Signet along the diagnostics-to-therapeutics trajectory this
coming year."
He added, "Signet's mission has been -- and will continue to be --
developing products that give physicians a better early warning system and
more timely intervention options to curb mortality rates, and promote improved
therapeutic outcomes for patients."
About Signet Laboratories, Inc.
Signet Laboratories, Inc. is a pioneering evidence-based medicine (EviMed)
company that is committed to developing and commercializing predictive
diagnostics and preventive drugs and therapies for critical disease states.
Evidence-based medicine is the treatment of diseases prior to their full
manifestation, with the goal of reducing their occurrence and preventing
disease progression by early identification of patients with increased risk
factors.
Drawing on long experience in developing diagnostic assays and antibodies
for disease detection and treatment, Signet's mission is to create novel
diagnostics and drugs for patients at risk for cancer, sepsis and renal
failure (SARF), neurodegenerative diseases including Alzheimer's, Parkinson's
and Huntington's, and prion diseases such as "Mad Cow" and vCJD.
In addition to diagnostics, drugs and therapies, Signet offers a complete
product line of over 400 manufactured antibodies, ELISA kits, detection
products and accessories in an FDA registered facility. Signet products are
available online, at http://www.signetlabs.com.
Contact Information
Company Contact Press Contact
Colleen Scott Mario Fante
Signet Laboratories, Inc. Signet Laboratories, Inc.
180 Rustcraft Road 180 Rustcraft Road
Dedham, MA 02026 Dedham, MA 02026
Phone: 781.915.1404 Phone: 617.448.8148
Fax: 781.461.2456 Fax: 781.461.2456
cscott@signetlabs.com mfante@signetlabs.com
SOURCE Signet Laboratories
 back to top
Related links:
http://www.signetlabs.com
CONTACT:
Colleen Scott, +1-781-915-1404,
cscott@signetlabs.com, or Mario Fante, +1-617-448-8148,
mfante@signetlabs.com both of Signet Laboratories, Inc.
|
